Multiparameter Immunophenotyping by Flow Cytometry in Multiple Myeloma: Advantages for Diagnosis and Minimal Residual Disease Monitoring. G. Requirand, J. Moreaux, A. Caraux, S. Raimbault, B. Klein. September 2012, Technical Jour n...
Cytometry Part B: Clinical CytometryMuthu Raja KR,Plasil M,Rihova L. Flow cytometry-based enumeration and functional characterization of cd8 t regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment[J].Cytometry B Clin Cytom,2013,(06)....
Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (N = 94), MGUS (N = 20) and multiple myeloma (MM, N = 52) vs. healthy adults (N = 30). ...
PURPOSE OF REVIEW: Although the input of multiparameter flow cytometry (MFC) into the clinical management of multiple myeloma patients has faced some reluctance, continuously growing evidence supports the utility of MFC in this disease. RECENT FINDINGS: MFC immunophenotyping of bone marrow and periphera...
At present, immunophenotyping is mandatory for the diagnosis and monitoring of acute leukemias and chronic lymphoproliferative disorders.1-4 By contrast, in multiple myeloma, the use of multiparametric flow cytometry in many clinical diagnostic laboratories is currently restricted to clinical research studies...
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. Purpose;To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (...
With the advent of multiparameter flow cytometry (FC) it became possible simultaneously analyze normal and malignant plasma cells (PC) in multiple myeloma (MM) patients. There is some data that residual normal bone marrow plasma cells (nBMPC) is of prog- nostic significance in plasma cells ...
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. We retrospectively reviewed the flow cytometry (FCM) data from bone marrow aspirates of multiple myeloma (MM) patients before and after autologous ste...
J San-Miguel2,20, M-V Mateos3,20, B Durie17,21, JJM van Dongen5,18,21 and A Orfao1,21 Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after...
The researchers note that response to treatment and prediction of recurrence can be assessed more reliably using new diagnostic methods, including allele-specific polymerase chain reaction, new-generation sequencing, and multicolor flow cytometry, which allow detection of MRD with sensitivity of 10−5 ...